KDR and renal cell carcinoma: Oosterwijk-Wakka et al. [94] evaluated the efficacy of combining sunitinib, a VEGFR-targeting tyrosine kinase inhibitor, with 177Lu-labeled cG250 radioimmunotherapy (RIT) in treating advanced renal cell carcinoma (RCC).